financetom
Business
financetom
/
Business
/
OpenAI bans suspected China-linked accounts for seeking surveillance proposals
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI bans suspected China-linked accounts for seeking surveillance proposals
Oct 7, 2025 5:22 AM

Oct 7 (Reuters) - OpenAI said on Tuesday it has banned

several ChatGPT accounts with suspected links to the Chinese

government entities after the users asked for proposals to

monitor social media conversations.

In its latest public threat report, OpenAI said some

individuals had asked its chatbot to outline social media

"listening" tools and other monitoring concepts, violating the

startup's national security policy.

The San Francisco-based firm's report raises safety concerns

over potential misuse of generative AI amid growing competition

between the U.S. and China to shape the technology's development

and rules.

OpenAI said it also banned several Chinese-language accounts

that used ChatGPT to assist phishing and malware campaigns and

asked the model to research additional automation that could be

achieved through China's DeepSeek.

The Chinese embassy in the U.S. did not immediately

respond to a request for comment on the report.

It also banned accounts tied to suspected

Russian-speaking criminal groups that used the chatbot to help

develop certain malware, OpenAI said.

The Microsoft ( MSFT )-backed startup has disrupted and reported more

than 40 networks since it began public threat reporting in

February last year and its models refused overtly malicious

prompts, the AI company added.

"We found no evidence of new tactics or that our models

provided threat actors with novel offensive capabilities," the

company said in the report.

OpenAI, which now has more than 800 million weekly ChatGPT

users, became the world's most valuable startup at a $500

billion valuation after completing a secondary share sale last

week.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ExlService Opens New Headquarters in Ireland
ExlService Opens New Headquarters in Ireland
Aug 11, 2025
09:35 AM EDT, 08/11/2025 (MT Newswires) -- ExlService Holdings ( EXLS ) said Monday it has opened new headquarters for international business in Dublin, Ireland and launched its new AI Innovation Lab. The company said the facility is in line with its commitment to making Ireland a strategic hub for its global operations, aiming to hire up to 200 technology...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Bitcoin Mining Stock CleanSpark Is Trending Monday: What's Going On?
Bitcoin Mining Stock CleanSpark Is Trending Monday: What's Going On?
Aug 11, 2025
CleanSpark Inc ( CLSK ) stock is trending to start the week as crypto markets continue to move higher. CleanSpark ( CLSK ) also announced a CEO transition on Monday. What Happened: Crypto-related stocks are seeing some buying interest amid broader strength across crypto markets. The momentum comes after President Donald Trump signed an executive order last week allowing for the addition...
Tiziana Life Sciences Says FDA Approved IND For Intranasal Foralumab Phase 2 Trial; Shares Up
Tiziana Life Sciences Says FDA Approved IND For Intranasal Foralumab Phase 2 Trial; Shares Up
Aug 11, 2025
09:36 AM EDT, 08/11/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday that US Food & Drug Administration approved an investigational new drug application for the phase 2a clinical trial of intranasal foralumab in patients with multiple system atrophy. The phase 2a trial is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab...
Copyright 2023-2026 - www.financetom.com All Rights Reserved